CD93: Recent advances and implications in disease

Mallary C. Greenlee-Wacker; Manuel D. Galvan; Suzanne S. Bohlson

doi:10.2174/138945012799424651

CD93: Recent advances and implications in disease

Mallary C. Greenlee-Wacker, Manuel D. Galvan, Suzanne S. Bohlson

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

While it has been known for some time that CD93 regulates several processes involved in innate immunity and inflammation including phagocytosis and adhesion, the function of CD93 in disease progression is only now being elucidated. Recent in vivo studies in mice, and genome wide studies in mice and humans, have provided clues about its molecular function. Following a comprehensive review of CD93 expression patterns, this review will focus on recent findings over the last three years that address the putative function of CD93 in inflammation and innate immunity.

Original language	English
Pages (from-to)	411-420
Number of pages	10
Journal	Current Drug Targets
Volume	13
Issue number	3
DOIs	https://doi.org/10.2174/138945012799424651
State	Published - Mar 2012
Externally published	Yes

Keywords

AA4.1
Adhesion
CD93
Group XIV
Inflammation
Innate immunity

Access to Document

10.2174/138945012799424651

Cite this

@article{c3528c84598d403a9bd3b6a1996d6521,

title = "CD93: Recent advances and implications in disease",

abstract = "While it has been known for some time that CD93 regulates several processes involved in innate immunity and inflammation including phagocytosis and adhesion, the function of CD93 in disease progression is only now being elucidated. Recent in vivo studies in mice, and genome wide studies in mice and humans, have provided clues about its molecular function. Following a comprehensive review of CD93 expression patterns, this review will focus on recent findings over the last three years that address the putative function of CD93 in inflammation and innate immunity.",

keywords = "AA4.1, Adhesion, CD93, Group XIV, Inflammation, Innate immunity",

author = "Greenlee-Wacker, {Mallary C.} and Galvan, {Manuel D.} and Bohlson, {Suzanne S.}",

year = "2012",

month = mar,

doi = "10.2174/138945012799424651",

language = "English",

volume = "13",

pages = "411--420",

journal = "Current Drug Targets",

issn = "1389-4501",

publisher = "Current Drug Targets",

number = "3",

}

TY - JOUR

T1 - CD93

T2 - Recent advances and implications in disease

AU - Greenlee-Wacker, Mallary C.

AU - Galvan, Manuel D.

AU - Bohlson, Suzanne S.

PY - 2012/3

Y1 - 2012/3

N2 - While it has been known for some time that CD93 regulates several processes involved in innate immunity and inflammation including phagocytosis and adhesion, the function of CD93 in disease progression is only now being elucidated. Recent in vivo studies in mice, and genome wide studies in mice and humans, have provided clues about its molecular function. Following a comprehensive review of CD93 expression patterns, this review will focus on recent findings over the last three years that address the putative function of CD93 in inflammation and innate immunity.

AB - While it has been known for some time that CD93 regulates several processes involved in innate immunity and inflammation including phagocytosis and adhesion, the function of CD93 in disease progression is only now being elucidated. Recent in vivo studies in mice, and genome wide studies in mice and humans, have provided clues about its molecular function. Following a comprehensive review of CD93 expression patterns, this review will focus on recent findings over the last three years that address the putative function of CD93 in inflammation and innate immunity.

KW - AA4.1

KW - Adhesion

KW - CD93

KW - Group XIV

KW - Inflammation

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=84857126778&partnerID=8YFLogxK

U2 - 10.2174/138945012799424651

DO - 10.2174/138945012799424651

M3 - Review article

C2 - 22206251

AN - SCOPUS:84857126778

SN - 1389-4501

VL - 13

SP - 411

EP - 420

JO - Current Drug Targets

JF - Current Drug Targets

IS - 3

ER -

CD93: Recent advances and implications in disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this